TOPLINE:

A tapering strategy for TNF inhibitors maintained low disease activity in patients with psoriatic arthritis (PsA) and those with axial spondyloarthritis (AxSpA) over 24 months. Protocol-driven tapering achieved a greater reduction in the mean dose of TNF inhibitors than routine care tapering, with both methods equally effective for disease control.

METHODOLOGY:

Previous 12-month results from an open-label, noninferiority, pragmatic trial (January 2019 to July 2020) conducted in the Netherlands showed that tapering of TNF inhibitors was noninferior to continued dosing for maintaining low disease activity in patients with PsA or AxSpA.

Participants in the original trial (aged 16 years or older with stable low disease activity for 6 or more months) were randomly assigned to eithe

See Full Page